You are here: Industry Insights > ADMA

News List

ADMA Biologics Announces Commercial Availability of Expanded Vial Size Offerings for BIVIGAM(R) and NABI-HB(R) americanpharmaceuticalreview
August 11, 2021
ADMA Biologics Inc. announced the commercial availability of additional vial sizes of BIVIGAM and NABI-HB, which are currently in stock and commercially available to U.S healthcare providers and patients.
ADMA Biologics Completes FDA Manufacturing Facility Inspection americanpharmaceuticalreview
July 21, 2021
ADMA Biologics Inc. announced the US FDA completed its Pre-Approval Inspection (“PAI”) of the Boca Raton, FL manufacturing facility related to ADMA's application for its VanRx SA25 Workcell aseptic fill-finish machine (“VanRx”).
ADMA Receives FDA Approval for Increased IVIG Production Scale contractpharma
April 30, 2021
ADMA Biologics, an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, has received approval from the FDA for the company’s expanded manufacturing process, enabling ...
FDA Approves ADMA Biologics Increased IVIG Production contractpharma
April 29, 2021
ADMA Biologics, Inc., a commercial biopharmaceutical company dedicated to specialty plasma-derived biologics, received approval from the U.S. FDA for the company’s expanded manufacturing process, enabling fractionation and purification of a ...
ADMA Biologics Begins Collection of COVID-19 Plasma from Recovered Patients americanpharmaceuticalreview
May 27, 2020
ADMA Biologics has commenced the collection of convalescent plasma through its wholly-owned subsidiary, ADMA BioCenters Georgia, from individuals who have recovered from COVID-19.
ADMA Announces It Will Reintroduce Bivigam Into the Market drugs
May 17, 2019
ADMA Announces It Will Reintroduce Bivigam Into the Market.
ADMA Biologics Reports FDA Compliance Status Update americanpharmaceuticalreview
September 06, 2018
ADMA Biologics announces that the U.S. Food and Drug Administration (FDA) inspection database classification website has been updated and confirms ADMA’s compliance status has improved to Voluntary Action Indicated (VAI).